A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Milnacipran 100 And 200 MG Daily in Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure.
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2014
At a glance
- Drugs Milnacipran (Primary)
- Indications Fibromyalgia
- Focus Pharmacodynamics
- Sponsors Forest Laboratories
- 04 Sep 2009 Planned number of patients changed from 270 to 321 as reported by ClinicalTrials.gov.
- 29 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 24 Apr 2008 Status changed from recruiting to in progress.